United States securities and exchange commission logo





                 September 21, 2021

       Duncan Peyton
       Chief Executive Officer
       4D pharma plc
       5th Floor, 9 Bond Court
       Leeds
       LS1 2JZ
       United Kingdom

                                                        Re: 4D pharma plc
                                                            Registration
Statement on Form F-1
                                                            Filed September 14,
2021
                                                            File No. 333-259501

       Dear Mr. Peyton:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

              Please contact Michael Davis at 202-551-4385 or Tim Buchmiller at
202-551-3635 with
       any questions.




                 Sincerely,


                 Division of Corporation Finance

                 Office of Life Sciences
       cc:                                              Steven V. Bernard, Esq.